Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations. — CFSMEATLAS
Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations.
Cochrane, M, Mitchell, E, Hollingworth, W et al. · Applied health economics and health policy · 2021 · DOI
Quick Summary
This review looked at whether ME/CFS treatments are worth the money they cost. Researchers found that cognitive behavioral therapy (CBT)—a type of talking therapy—appears to be cost-effective for some adults with ME/CFS, though results varied depending on how it was delivered. There is much less evidence for other treatments, and very little research on what works best for children with ME/CFS.
Why It Matters
This systematic review addresses a critical gap in ME/CFS care: understanding which treatments provide good value for patients and healthcare systems. With ME/CFS causing substantial disability and economic burden, evidence on cost-effective interventions helps patients, clinicians, and policymakers make informed decisions about resource allocation and treatment selection.
Observed Findings
Cognitive behavioral therapy was evaluated in five economic studies, the most frequently examined intervention.
Three trials found evidence supporting CBT as cost-effective for adults, though findings were not uniform across settings.
Graded exercise therapy had limited cost-effectiveness evidence from two trials.
Only one economic evaluation assessed interventions specifically for children with ME/CFS.
Informal care costs and productivity losses were identified as important but often undervalued in economic analyses.
Inferred Conclusions
CBT shows promise as a cost-effective treatment for some adults with ME/CFS, but cost-effectiveness depends on contextual factors including session duration and frequency.
The evidence base for ME/CFS intervention cost-effectiveness is severely limited, representing a 'patchwork' rather than comprehensive guidance.
The field lacks adequate economic evidence for pharmacological interventions and child-focused therapies, representing major research gaps.
Future economic evaluations must include longer follow-up periods and larger sample sizes to provide robust evidence.
Remaining Questions
Which specific characteristics of CBT delivery (duration, frequency, format) maximize cost-effectiveness for different patient subgroups?
What This Study Does Not Prove
This review does not prove that CBT or GET are universally effective or safe for all ME/CFS patients—it only addresses cost-effectiveness in selected trial populations. The review cannot establish optimal treatment duration, frequency, or individual patient factors predicting who will benefit economically. The limited pediatric evidence means findings may not apply to children with ME/CFS.